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ABSTRACT. Mobile electrocardiograms (ECGs) (mECGs) using smartphone applications are
an emerging technology. In the coronavirus disease 2019 (COVID-19) era, minimizing patient
contact has gained increasing importance. Additionally, increased QT/corrected QT (QTc) monitoring has concurrently been required. The KardiaMobile 6L ECG device, cleared by the United
States Food and Drug Administration (FDA) for recording ECGs, along with the KardiaStation
tablet application is a platform (AliveCor, Mountain View, CA, USA) that addresses these two
issues. A team of residents, fellows, hospitalists, and cardiologists identified inpatients in need
of QT/QTc interval monitoring to pilot the adoption of a system composed of a KardiaMobile 6L
ECG device with the accompanying KardiaStation tablet application. Concurrent standard ECGs
provided validation. Adoption and performance issues were recorded. Four patients agreed to participate in QT/QTc interval monitoring, three of whom were positive for severe acute respiratory
syndrome coronavirus 2 viral infection. After basic instructions were given to the patients and
their clinical nurses, all patients recorded mECGs successfully. Patients were able to record their
own mECG tracings at least once without any assistance. The 12-lead ECGs and mECGs each
showed the correct rhythm, and the measured QTc intervals on each modality were consistently
acceptable (< 500 ms). Contactless ECGs were successfully uploaded to KardiaStation for QT/
QTc interval measurement and archiving. In this study, we showed that an FDA-cleared product,
KardiaMobile 6L, has the ability to provide high-quality contactless ECGs for reliable QT/QTc
interval measurements. Hospitalized patients were able to perform recordings when requested after
receiving simple instructions at the time of first use. This technology has applications during the
COVID-19 pandemic and beyond.
KEYWORDS. Contactless care, COVID-19, KardiaMobile, KardiaStation, QT/QTc interval.
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Introduction
Patients with prolonged QT/corrected QT (QTc) intervals are at a greater risk for torsades de pointes and
subsequent ventricular fibrillation and sudden cardiac
death.1 A prolonged QTc interval is a known side effect
of several hundred medications, including hydroxychloroquine and azithromycin, two drugs that were used to
treat patients with coronavirus disease 2019 (COVID-19)
in abundance early on in the clinical experience with
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this viral condition.1–3 Patients with known and suspected arrhythmias are common in outpatient practice.4
Advances in mobile technology are widely available
and extend the scope of remote monitoring beyond that
of conventional medically prescribed products. A commercially available mobile electrocardiogram (mECG)
device, KardiaMobile (AliveCor, Mountain View, CA,
USA), is relatively inexpensive and works with a smartphone or tablet application; using sensors for fingers
from the right and left hands, it provides a 30-second
or longer tracing corresponding to lead I of a standard
12-lead ECG. Compared with simple pulse rate monitors,
the ability to record ECG information is more useful for
arrhythmia diagnosis.5 Beyond the ability of patients to
record their own mECGs, AliveCor offers a subscription
service, KardiaPro, which logs the mECG recordings for
collection and review. Since 2017, our institution, Thomas
Jefferson University Hospital, has registered outpatients
to this encrypted, practice-managed service.

describe our experience with this technology. The purpose
of this case series was to assess the feasibility of recording
using the commercially available mECG device, KardiaMobile 6L, along with a tablet application (KardiaStation;
AliveCor) in inpatients needing intermittent ECG monitoring. We also sought to document the ease of use of contactless ECG recordings and to compare contactless ECG
recordings from the KardiaMobile 6L with standard ECG
recordings, which require medical personnel to come into
close proximity with COVID-19–positive patients. Our
aim was to derive clinical practice lessons for the use of
KardiaMobile 6L beyond the COVID-19 pandemic, as we
believe that heightened infectious disease protocols minimizing health care provider and patient exposure will be
the “new norm” in inpatient management.

The KardiaMobile mECG device has been used experimentally in a variety of ambulatory settings to detect
arrhythmias and conduction system abnormalities such
as atrial fibrillation, to monitor QT/QTc intervals during
antiarrhythmic drug initiation, and to diagnose myocardial infarction.6–10 These proof-of-concept studies largely
have depended on single-lead measurements made manually, which provide less information than what is available with a multilead analysis. Previously, we developed
a method to record alternate ECG leads (aside from lead
I) using the mECG device.11 We observed that patients
were able to use the technology without difficulty. In May
2019, the United States Food and Drug Administration
(FDA) granted clearance to the KardiaMobile 6L device,
the first-ever, personal six-lead ECG device; KardiaMobile 6L records six of the 12 leads usually obtained from
a standard ECG (ie, the limb leads are recorded but not
the precordial leads). A six-lead tracing is recorded by
placing a person’s right and left fingers or thumbs on the
corresponding electrodes on the top surface of the device
while simultaneously placing the electrode on the bottom
surface of the device against the skin on the left lower
extremity.

Eligible participants included male and female COVID19–positive patients or patients requiring ECG monitoring who were at least 18 years of age. All patients were
diagnosed using nasal swabs. Study participants were
not on telemetry but required intermittent ECG monitoring and had no prior experience using an mECG device.
Among suspected or confirmed COVID-19–positive
patients, respiratory isolation precautions were used.
Hydroxychloroquine and azithromycin were administered due to the experimental use of these treatments for
the management of COVID-19–related clinical sequelae
at the time of the study. We included patients with QTc
interval values of greater than 500 ms, as we deemed them
to be at high risk for torsades de pointes. We excluded
patients unwilling or unable to use the KardiaMobile 6L
device and those who needed continuous telemetry.

On March 23, 2020, the FDA issued an enforcement
policy to help expand the availability and capability of
noninvasive remote monitoring devices, such as Kardia
Mobile 6L, to facilitate patient monitoring while reducing
patient and health care provider contact and exposure to
patients positive for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection for the duration
of the COVID-19 public health emergency. This policy
enabled the use of the KardiaMobile 6L device for QT/
QTc interval monitoring to improve patient safety while
administering potential QT/QTc interval–prolonging
medications.5
Given the limited experience with using mECGs in
the inpatient setting and the use of potential QT/QTc
interval–prolonging medications (hydroxychloroquine
and azithromycin) in COVID-19 patients, we sought to
4434

Methods
Patient population

Endpoints
The primary goals of this study were to assess the feasibility of obtaining recordings using the commercially
available KardiaMobile 6L mECG device together with
a tablet application (KardiaStation) among inpatients
needing intermittent ECG monitoring and to qualitatively compare the results with standard 12-lead ECG
recordings. The secondary purpose was to determine
whether patients could perform their own recordings
with the device when the health care provider is outside
the room (ie, a contactless recording). We hypothesized
that KardiaMobile 6L would be able to yield an accurate
ECG recording in a contactless manner.

Study procedures
The manufacturer provided several KardiaMobile 6L
devices, a dedicated iPad tablet (Apple, Inc., Cupertino,
CA, USA), and a demonstration version of the
KardiaStation application (Figure 1). On the same tablet, we created a shortcut to our institutional KardiaPro
account. Additionally, we connected to the hospital
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Figure 1: The KardiaMobile 6L device. A: By placing two
thumbs on the device and holding it against the knee, a
six-lead ECG recording can be taken. B: A clinician uses the
KardiaStation app on an iPad tablet outside of the patient’s
room while the patient takes measurements inside their
room. Images courtesy of AliveCor.

WiFi and had access to the institutional electronic health
records.
The multidisciplinary care team, consisting of cardiologists, hospitalists, and nurses, met initially by video conference to discuss the mECG product and software. Once
a hospitalist identified a potential patient, the team members communicated electronically about eligibility for
inclusion. A resident or fellow (D. R. F., E. S. F., or D. J. F.)
spoke either to the patient’s nurse or directly to the patient
to explain the system; consent for patient inclusion in this
research was attained during the first encounter between
the patient and the cardiologist or cardiology fellow. One
of the team members showed the nurse how to complete a recording by using a demonstration device and
the iPad. The nurse then had the opportunity to ask any

clarifying questions and to ensure she or he u
 nderstood
how to use the device. To minimize direct contact, these
conversations were generally held via telephone with the
health care provider outside the room. The next time that
the nurse went into the room for clinical care, she or he
educated the patient on how to use the device. Patients
were also provided with written instructions in English.
Within their rooms, patients were brought to within 10
feet of the door (Bluetooth range). One of the cardiologists then stood at the closed door while the patient performed the recordings (Figure 1). Patients completed two
recordings using the KardiaMobile 6L device with the
health care provider outside the room. After a successful
recording, the cardiologist let the patient know that the
recording had been completed. A nurse was sometimes in
the room during the initial recording, but to fulfill other
caregiving responsibilities rather than assist with the
recording.
Next, WiFi connectivity was verified and QT/QTc
interval analysis was requested through the KardiaPro
account. Once requested, the QT/QTc interval analysis
was performed by BioTelemetry, Inc. (Malvern, PA, USA),
an independent third-party QTc measuring service that
has performed nearly 4,000 QT interval measurements
to date. Within one hour, one of the cardiologists then
logged on to the KardiaPro website to review the mECG,
the automatic interpretation, and the QT/QTc interval
measurements reported by the third-party source. At the
time of discharge, the three COVID-19–positive patients
kept the provided KardiaMobile 6L devices and were told
about the ability to subscribe to the Kardia system as outpatients. At the cardiologist’s or cardiology fellow’s discretion, patients also received nonmobile ECGs for QT/
QTc interval monitoring within one day of the mobile
recordings.

Statistical methods
This was a descriptive study without statistical analysis. This study was approved by the Thomas Jefferson
University Hospital Institutional Review Board.

Results
Of the six consecutive patients approached for the study,
four agreed to participate. The two who did not participate stated that they were not interested. Demographics,
ECG results, and mECG results are recorded in Table 1.
Representative ECG and mECG recordings are shown in
Figure 2.

Patient 1
Patient 1 was a 45-year-old man with a medical history
of renal cancer (who underwent left nephrectomy and a
renal transplant), hypertension, morbid obesity, and sleep
apnea. The patient presented with progressive fatigue and
intermittent chills for five days and loose stools for one day.
On the advice of his nephrologist, the patient presented to
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Table 1: Patient Demographics and ECG Measurements Taken During the Study
Patient Age/Sex/ Recording
ECG/mECG
QT/QTc
Patient Able
No.
COVID-19
Interpretation (Rate) Interval (ms) to Record ECG
Status
Independently?
1

45 years
Male
Positive

2

48 years
Male
Positive

3

67 years
Male
Negative

4

96 years
Female
Positive

ECG 1
ECG 2
Kardia 1
Kardia 2
ECG 1
ECG 2
Kardia 1
Kardia 2
ECG 1
ECG 2
Kardia 1
Kardia 2
ECG 1
ECG 2

Sinus rhythm (83 bpm)
Sinus rhythm (88 bpm)
Tachycardia (102 bpm)
Normal (97 bpm)
Sinus rhythm (97 bpm)
Sinus rhythm (89 bpm)
Normal (99 bpm)
Tachycardia (103 bpm)
AF (97 bpm)
AF (103 bpm)
Possible AF (98 bpm)
Possible AF (92 bpm)
AF (103 bpm)
AF (120 bpm)

372/437
372/450
360/469*
350/445*
380/483
384/468
327/419
363/478
348/442
376/492
373/462
417/514
353/462
339/479

N/A
N/A
Yes
Yes
N/A
N/A
Yes
Yes
N/A
N/A
Yes
Yes
N/A
N/A

Kardia 1
Kardia 2

N/A
Possible AF (83 bpm)

N/A
363/430

Yes
Yes

AF: atrial fibrillation; COVID-19: coronavirus disease 2019; ECG: electrocardiogram;
mECG: mobile electrocardiogram; N/A: not available; QTc: corrected QT.
*Manual measurement.

the emergency department for evaluation. An evaluation
confirmed SARS-CoV-2 infection, and he was started on
a five-day course of hydroxychloroquine. He was able to
complete two recordings using the KardiaMobile 6L with
the health care provider outside the room. At discharge,
his inflammatory markers remained elevated but stable.

Patient 2
Patient 2 was a 48-year-old Spanish-speaking man with no
significant medical history who presented with a cough
and worsening dyspnea; an evaluation subsequently confirmed SARS-CoV-2 infection. During his hospitalization,
he never required supplemental oxygen and was able to
ambulate without desaturation while breathing room air.
He was given a several-day course of hydroxychloroquine,
which was initiated upon admission. He remained on
room air with stable inflammatory m
 arkers and was discharged with instructions for COVID-19 precautions. His
nurse provided instructions to him in Spanish, and he was
able to complete two recordings using the KardiaMobile
6L with the health care provider outside the room.
As standard of care, this patient also received nonmobile
ECGs for QT/QTc interval monitoring within one day
of the mobile recordings. A comparison of the two ECG
readings revealed similar automatic rhythm interpretations and QT/QTc interval calculations.

Patient 3
Patient 3 was a 67-year-old man with advanced systolic
heart failure and persistent atrial fibrillation who presented with acute decompensated heart failure. Because of
4436

the lack of response to therapies in the intensive care unit,
he was transferred to the telemetry ward for consideration
of palliative care options. After an unanticipated clinical
improvement with diuretic therapy and following further
discussion with the patient, he agreed to slowly intensify
medical therapy again. However, he requested minimal
invasiveness and testing. Given this request, we proceeded
with implementing contactless ECG monitoring. Although
he did not have COVID-19, his diagnosis of significant cardiomyopathy and anticipated electrolyte shifts clinically
justified the use of intermittent ECG monitoring. He was
able to complete two recordings using the KardiaMobile 6L
device with the health care provider outside of the room.

Patient 4
Patient 4 was a 96-year-old woman with atrial fibrillation
treated with anticoagulation therapy, mild aortic stenosis, dyslipidemia, hypertension, chronic kidney disease,
and anemia who presented with subjective palpitations
and was found to have atrial fibrillation with a rapid
response. One week prior to the current admission, she
was hospitalized for near-syncope and was found to be
positive for COVID-19. She was treated with hydroxychloroquine for five days and also with ceftriaxone and
azithromycin for superimposed pneumonia. Due to variable heart rates, ECG monitoring was required. Despite
our initial concerns about this patient’s mobility, “technology literacy,” and frailty, she was able to complete two
recordings using the KardiaMobile 6L device with the
health care provider outside the room.
This patient also received a nonmobile ECG within one
day for validation. A comparison of the two ECG readings
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Figure 2: Representative ECGs and mECGs from two patients. A: ECG from patient 2. B: Six-lead mECG from patient 2. Note that
the automatic rhythm interpretations are correct and the QTc intervals are less than 500 ms. Note that 40-ms vertical gridlines
have been added to aid in the ability to measure the QT interval manually.

revealed similar automatic rhythm interpretations and
QTc interval calculations.

Key lessons
Key lessons from our case series are noted in Tables 2
and 3. These include the need for both patient and provider education about the logistics and utility of this

ECG method as well as the need for resources beyond
the KardiaMobile 6L device itself (ie, a reliable wireless
Internet connection and a tablet computer).

Discussion
mECG devices have previously been used in ambulatory
detection of atrial fibrillation with high sensitivity and
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Figure 2: Continued. C: ECG from patient 4. D: Six-lead mECG from patient 4. Note that the automatic rhythm interpretations
are correct and the QTc intervals are less than 500 ms. Note that 40-ms vertical gridlines have been added to the mECG tracings
to aid in the ability to measure the QT interval manually.

specificity. In this case series, we found that patients were
able to use the mECG product for QT/QTc interval monitoring in an inpatient setting and that accurate recordings were obtainable despite the health care provider not
being in contact with the patient. Although not assessed
formally, repeat measurements anecdotally required less
instruction than the initial measurement and could be
completed within minutes. Furthermore, this technology delivered consistent, accurate results among special
patient populations (eg, non-English speakers, patients
with advanced heart failure, and elderly and frail
4438

individuals). Furthermore, we observed that this method
of ECG monitoring can be reliably deployed among hospitalized COVID-19–positive patients. Our case series
provides evidence that the use of KardiaMobile 6L can
likely be extended beyond inpatient COVID-19–related
rhythm monitoring and into the outpatient realm.
KardiaMobile 6L uses a unique technology that can record
high-quality ECGs of all six limb leads. The technology
allows the recordings to be transferred from a mobile
device via KardiaStation to an independent diagnostic
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Table 2: Key Lessons Learned During the Adoption of the
KardiaStation System
• Need to educate the stakeholders, composed of a multi
disciplinary team of nurses, cardiologists, other physicians,
and patients, about the device and method
• Information about the product and a demonstration of its
use for patients were required
• Need the KardiaMobile 6L device and a recording device,
such as an iPad, equipped with the KardiaStation application and KardiaPro software to review the recordings and
QT interval
• Need reliable wireless connectivity to review the tracings
and to send the information to other participating services
(eg, to BioTelemetry, Inc. for QT/QTc interval measurements)

QTc: corrected QT.
Table 3: Key Lessons to Apply Beyond the COVID-19
Pandemic
• Rhythm monitoring can be accomplished with a simplified
WiFi-enabled device and application
• The ability to record via KardiaMobile 6L expands the tools
available to obtain ECG recordings (ie, do not need a 12-lead
ECG machine only)
• Monitoring the QTc interval for values > 500 ms was reliable
in this situation and can be applied during QT monitoring in
the context of other drugs (eg, antiarrhythmics)
• Patients can continue to monitor rhythm, rate, and QTc
interval as outpatients with the same device

ECG: electrocardiogram; QTc: corrected QT.

testing facility that can quantify QT/QTc intervals rapidly and then return the information to frontline health
care providers. The recordings from the KardiaStation
application automatically synchronize to the KardiaPro
physician portal, where clinicians can review the collected data. Unlike most ambulatory ECGs, by virtue
of including all six of the limb leads, KardiaMobile 6L
includes lead II data, which frequently offer a more accurate view of the QT/QTc interval than data for lead I.12
During times of crisis such as the COVID-19 pandemic,
when QT/QTc interval–prolonging medications are
used, there is high utility in reliably measuring the QT/
QTc interval accurately for both inpatient and outpatient
use. KardiaMobile 6L offers expedited recordings and,
within minutes, can provide information to health care
providers. The device is small and recordings can be performed by patients within their rooms. This minimizes
close contact with frontline health care providers, potentially reducing the spread of COVID-19 or other infectious diseases to essential personnel and other patients.
Furthermore, because of its availability and ease of use,
the KardiaMobile 6L device addresses the potential shortage of remote ECG machines in a cost-effective manner
given the infection-control protocols.13
The use of wearable and patient-owned medical products is likely to increase in the era of heightened infectious disease protocols during and following the COVID19 pandemic. Minimizing patient-to-provider and

patient-to-patient contact is a priority in every hospital
process. Essential processes that subject health care providers to high patient exposure, ranging from patient
transport to intensive care unit procedures, must be
reconceptualized. The process of heart rhythm monitoring is no exception, as placing, changing, and removing
ECG leads accurately carry a high risk of exposure for the
frontline health care provider. Minimizing this risk illustrates the importance of KardiaMobile 6L and use of an
accurate, mobile, patient-centric technology in the inpatient setting. By increasing diagnostic accuracy and by
expanding the automated diagnostic possibilities, there
is likely to be more widespread acceptance by patients
and health care providers regarding the utility of mECG
devices and similar technology.

Limitations
This study was a limited case series of consecutive patients
willing to participate. A larger sample may reveal issues
that were not observed in this investigation. Furthermore,
a larger study would be needed to confirm the accuracy
of using patient-operated, externally analyzed mECG
devices to detect significant QTc interval prolongation. In
addition, due to the limited availability of nonmobile ECGs
and telemetry, we were unable to concurrently measure
patients using both mECGs and nonmobile ECGs.

Conclusion
Mobile technology is available for heart rhythm monitoring and has demonstrated diagnostic accuracy and the
yield of high-quality ECG recordings. In this study, we
showed that an available product, KardiaMobile 6L, had
the ability to provide contactless ECGs with acceptable
QT/QTc interval measurements. Hospitalized patients
were able to perform recordings with simple instructions
at the time of first use. Given the heightened importance
of minimizing infectious disease risk during and beyond
the COVID-19 pandemic, we strongly believe that
KardiaMobile 6L can be applied to safely and effectively
monitor patients at high risk for arrhythmia in both inpatient and outpatient settings.
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